|
|
|||||||||
CA: A Cancer Journal for Clinicians, Vol 47, Issue 1 52-64, Copyright © 1997 by American Cancer Society
E. R. Fisher
Management of ductal carcinoma in situ has become one of the most
controversial topics in breast disease. While mastectomy has been the
traditional treatment, many now feel it is excessive in most cases. As a
result, a great effort has been made to identify pathobiological
characteristics of DCIS that can be used to stratify appropriate treatment
decisions. This article reviews efforts to relate pathobiological
characteristics to disease management and provides treatment
recommendations based on the latest evidence.
ARTICLES
Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast
National Surgical Adjuvant Breast and Bowel Project, Shadyside Hospital, Pittsburgh, Pennsylvania, USA.
This article has been cited by other articles:
![]() |
E. R. Fisher and B. Fisher Relation of a Recurrent Intraductal Carcinoma (Ductal Carcinoma In Situ) to the Primary Tumor J Natl Cancer Inst, February 16, 2000; 92(4): 288 - 289. [Full Text] [PDF] |
||||
![]() |
B. S. Reddy, T. Kawamori, R. A. Lubet, V. E. Steele, G. J. Kelloff, and C. V. Rao Chemopreventive Efficacy of Sulindac Sulfone against Colon Cancer Depends on Time of Administration during Carcinogenic Process Cancer Res., July 1, 1999; 59(14): 3387 - 3391. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |